Skip to main content
SpringerLink
Log in

Novel Molecular Targets for Drug-Treatment of Epilepsy

  • Chapter
  • First Online:
Epilepsy Towards the Next Decade

Part of the book series: Contemporary Clinical Neuroscience ((CCNE))

Abstract

Nowadays several antiepileptic drugs (AEDs) are available for the treatment of patients with epilepsy. Nevertheless, up to 30 % of patients continue to present recurrent seizures. So, the challenge for new more efficacious and better tolerated drugs is continuing. Advances in understanding of pathophysiology of epilepsy and in the physiology of ion channels and other molecular targets provide opportunities to create new and improved AEDs. Potentially interesting molecular targets include KCNQ-type K+ channels, SV2A synaptic vesicle protein, ionotropic and metabotropic glutamate receptors. The pipeline for the development of new AEDs with novel mechanisms of action is narrowing with only a few interesting compounds on the immediate horizon. In fact, only perampanel (modulates AMPA mediated neurotransmission) and brivaracetam (binds to SV2A protein and sodium channel) are likely to reach the market-place in the next 3 years. Eslicarbazepine has approved in the last year as add-on treatment for partial onset seizures.

This chapter reviews the available information on various classes of molecules that are in the pipeline for the treatment of epilepsy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Almeida L, Soares da Silva P (2007) Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 4:88–96

    Article  CAS  PubMed  Google Scholar 

  • Almeida L, Minciu I, Nunes T, Falcão A, Magureanu SA, Soares-da-Silva P (2008) Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescent with epilepsy. J Clin Pharmacol 48:966–977

    Article  CAS  PubMed  Google Scholar 

  • Almeida L, Bialer M, Soares da Silva P (2009) Eslicarbazepine acetate. In: Shorvon S, Perucca E, Engel J (eds) The treatment of Epilepsy, 3rd edn. Blackwell, Oxford, pp 485–498

    Chapter  Google Scholar 

  • Ambrosio AF, Silva AP, Araujo I, Malva JO, Soares-da-Silva P, Carvalho AP et al (2000) Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol 406:191–201

    Article  CAS  PubMed  Google Scholar 

  • Ambrosio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM (2001) Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivates of carbazepine, due to blockade of sodium but not calcium channel. Biochem Pharmacol 61:1271–1275

    Article  CAS  PubMed  Google Scholar 

  • Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA et al (1999) Anticonvulsivant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide derivative. J Med Chem 42:2582–2587

    Article  CAS  PubMed  Google Scholar 

  • Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P (2010) Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilesy Res 89:278–285

    Article  CAS  Google Scholar 

  • Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA et al (2007) Seletracetam (UCB 44212). Neurother 4(1):117–122

    Article  CAS  Google Scholar 

  • Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2013) Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 103(1):2–30

    Article  PubMed  Google Scholar 

  • Binnie CD, Kasteleijn-Nolst Trenité DGA, De Korte RA (1986) Photosensitivity as a model for acute antiepileptic drug studies. Electroencephalogr Clin Neurophysiol 63:35–41

    Article  CAS  PubMed  Google Scholar 

  • Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S (2014) Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 55(1):57–66

    Article  CAS  PubMed  Google Scholar 

  • Brodie MJ (2010) Antiepileptic drug therapy the story so far. Seizure 19(10):650–655

    Article  PubMed  Google Scholar 

  • Brown ME, El-Mallakh RS (2010) Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures. Ther Clin Risk Manag 6:103–109

    PubMed Central  PubMed  Google Scholar 

  • Cunha RA, Coelho JE, Costenla AR, Lopes LV, Parada A, de Mendonça A et al (2002) Effects of carbazepine and novel 10,11-dihidro-5H-dibenz(b,f)azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices. Pharmacol Toxicol 90:208–213

    Article  CAS  PubMed  Google Scholar 

  • Di Prospero NA, Gambale JJ, Pandina G, Ford L, Girgis S, Moyer JA et al (2014) Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: A placebo-controlled, exploratory study. Epilepsy Res 108(4):709–716

    Article  CAS  PubMed  Google Scholar 

  • Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P (2007) Eslicarbazepine acetate: a double blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 48:497–504

    Article  CAS  PubMed  Google Scholar 

  • Elger C, Halasz P, Maia J, Almeida L Soares-da-Silva P (2009) BIA-2093–301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase 3 study. Epilepsia 50:454–463

    Article  CAS  PubMed  Google Scholar 

  • Falcao A, Pinto R, Nunes T, Soares-da-Silva P (2013a) Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res 106(1–2):244–249

    Article  CAS  Google Scholar 

  • Falcao A, Vaz-da-Silva M, Gama H, Nunes T, Almeida L, Soares-da-Silva P (2013b) Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healty women. Epilepsy Res 105:368–376

    Article  CAS  Google Scholar 

  • Faught E, Holmes GL, Rosenfeld WE, Novak G, Neto W, Greenspan A et al (2008) Randomized, controlled, dose ranging trial of carisbamate for partial-onset seizures. Neurology 71:1586–1593

    Article  CAS  PubMed  Google Scholar 

  • Franco V, Crema F, Iudice A, Zaccara G, Grillo E (2013) Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res 70(1):35–40

    Article  CAS  PubMed  Google Scholar 

  • Francois J, Ferrandon A, Koning E, Nehlig A (2005) A new drug RWJ 333369 protects limbic areas in the lithium-pilocarpine model of epilepsy and delays or prevents the occurrence of spontaneous seizures. Epilepsia 46(Suppl 8):269–270

    Google Scholar 

  • French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A et al (2012) Adjunctive Perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79:589–596

    Article  PubMed Central  PubMed  Google Scholar 

  • French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D et al (2013) Evalutation of adjunctive Perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 54:117–125

    Article  CAS  PubMed  Google Scholar 

  • Gillard M, Fuks B, Leclercq K, Matagne A (2011) Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 664(1–3):36–44

    Article  CAS  PubMed  Google Scholar 

  • Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J Soares-da-Silva P (2009) BIA-2093–303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 120:281–287

    Article  CAS  PubMed  Google Scholar 

  • Gil-Nagel A, Elger C, Ben-Menachem E, Halász P, Lopes-Lima J, Gabbai AA et al (2013) Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 54:98–107

    Article  CAS  PubMed  Google Scholar 

  • Gormsen L, Finnerup NB, Almqvist PM, Jensen TS (2009) The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg 108(4):1311–1319

    Article  CAS  PubMed  Google Scholar 

  • Halasz P, Cramer JA, Hodoba D, Członkowska A, Guekht A, Maia J et al (2010) Long term efficacy of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 51:1963–1969

    Article  CAS  PubMed  Google Scholar 

  • Hufnagel A, Ben-Menachem E, Gabbai AA, Falcão A, Almeida L, Soares-da-Silva P (2013) Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res 103:262–269

    Article  CAS  PubMed  Google Scholar 

  • Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B et al (2008) SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54(4):715–720

    Article  CAS  PubMed  Google Scholar 

  • Kasteleijn-Nolst Trenité D Rubboli G, Hirsch E, Martins da Silva A, Seri S, Wilkins A et al (2012) Methodology of photic stimulation revisited: updated European algorithm for visual stimulation in the EEG laboratory. Epilepsia 53:16–24

    Article  PubMed  Google Scholar 

  • Kasteleijn-Nolst Trenité DG, Biton V, French JA, Abou-Khalil B, Rosenfeld WE, Diventura B et al (2013) Kv7 potassium channel activation with ICA-105665 reduces photoparoxysmal EEG responses in patients with epilepsy. Epilepsia 54(8):1437–1443

    Article  PubMed Central  PubMed  Google Scholar 

  • Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J et al (2012a) Randomized phase 3 study 306: adjunctive Perampanel for refractory partial-onset seizures. Neurology 78:1408–1415

    Article  CAS  Google Scholar 

  • Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N et al (2012b) Tolerability and safety of Perampanel: two randomized dose-escalation studies. Acta Neurol Scand 125:8–15

    Article  CAS  Google Scholar 

  • Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S (2014) Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 55(1):38–46

    Article  CAS  PubMed  Google Scholar 

  • Löscher W, Klitgaard H, Twyman RE, Schmidt D (2013) New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 12(10):757–756

    Article  PubMed  Google Scholar 

  • Margineanu DG, Klitgaard H (2009) Brivaracetam inhibits spreading depression in rat neocortical slices in vitro. Seizure 18(6):453–456

    Article  PubMed  Google Scholar 

  • Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H (2008) Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 154(8):1662–1671

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Matagne A, Margineanu DG, Potschka H, Löscher W, Michel P, Kenda B et al (2009) Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Eur J Pharmacol 614(1–3):30–37

    Article  CAS  PubMed  Google Scholar 

  • Mattson RH, Cramer JA, Collins JF (1992) A comparison of valproate with carbamazepine for the treatment of partial seizures and secondary generalized tonic-clonic seizures in adults. N Eng J 327:765–771

    Article  CAS  Google Scholar 

  • Meldrum BS, Rogawski MA (2007) Molecular targets for antiepileptic drug development. Neurother 4(1):18–61

    Article  CAS  Google Scholar 

  • Parada A, Soares da Silva P (2002) The novel anticonvulsivant BIA2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem Int 40:435–440

    Article  CAS  PubMed  Google Scholar 

  • Perucca E (2009) What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia 50(Suppl 12):49–50

    Article  PubMed  Google Scholar 

  • Perucca E, Tomson T (2011) The pharmacological treatment of epilepsy in adults. Lancet Neurol 10(5):446–456

    Article  CAS  PubMed  Google Scholar 

  • Perucca E, French J, Bialer M (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6(9):793–804

    Article  CAS  PubMed  Google Scholar 

  • Pitkanen A, Mathiesen C, Ronn LC, Møller A, Nissinen J (2007) Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res 74(1):45–54

    Article  PubMed  Google Scholar 

  • Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW et al (2012) Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 35:15–20

    Article  CAS  PubMed  Google Scholar 

  • Rocha JF, Vaz-da-Silva M, Almeida L, Falcão A, Nunes T, Santos AT et al (2009) Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther 7:255–261

    Article  Google Scholar 

  • Roeloffs R, Wickenden AD, Crean C, Werness S, McNaughton-Smith G, Stables J et al (2008) In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluorobenzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models. J Pharmacol Exp Ther 326:818–828

    Article  CAS  PubMed  Google Scholar 

  • Rogawski MA (2002) Principles of antiepileptic drug action. In Levy RH, Mattson RH, Meldrum BS, Perucca E (eds) Antiepileptic drugs, 5th ed. Lippincot Williams & Wilkins, Philadelphia, pp 3–22

    Google Scholar 

  • Rogawski MA (2011) Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 11:56–63

    Article  PubMed Central  PubMed  Google Scholar 

  • Rogawski MA (2013) AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand 197:9–18

    Article  Google Scholar 

  • Rogawski MA, Bazil CW (2008) New molecular targets for antiepileptic drugs: alpha (2) delta, SV2A, and K(v)7/KCNQ/Mpotassium channels. Curr Neurol Neurosci Rep 8:345–352

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rogawski MA, Loscher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553–564

    Article  CAS  PubMed  Google Scholar 

  • Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A (2008) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 66(1):71–75

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Russo E, Gitto R, Citraro R, Chimirri A, De Sarro GB (2012) New AMPA antagonists in epilepsy. Expert Opin Investig Drugs 21(9):1371–1389

    Article  CAS  PubMed  Google Scholar 

  • Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S (2014) Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 55(1):47–55

    Article  CAS  PubMed  Google Scholar 

  • Sander JW (2004) The use of antiepileptic drugs–principles and practice. Epilepsia 45(S6):28–34

    Article  PubMed  Google Scholar 

  • Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E et al (2007) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 63(6):680–688

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sargentini-Maier ML, Sokalski A, Boulanger P, Jacobs T, Stockis A (2012) Brivaracetam disposition in renal impairment. J Clin Pharmacol 52(12):1927–1933

    Article  CAS  PubMed  Google Scholar 

  • Shorvon S (2000) Oxcarbazepine: a review. Seizure 9:75–79

    Article  CAS  PubMed  Google Scholar 

  • Sperling MR, Greenspan A, Cramer JA, Kwan P, Kälviäinen R, Halford JJ et al (2010) Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo controlled trials. Epilepsia 51:333–343

    Article  CAS  PubMed  Google Scholar 

  • Stockis A, Sargentini-Maier ML, Horsmans Y (2013) Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol 53(6):633–641

    Article  CAS  PubMed  Google Scholar 

  • Vaz-da-Silva M, Costa R, Soares E, Maia J, Falcão A, Almeida L et al (2009) Effects of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol 23:504–514

    Article  Google Scholar 

  • Verrotti A, Loiacono G, Rossi A, Zaccara G (2014) Eslicarbazepine acetate: an update on efficacy and safety in epilepsy. Epilepsy Res 108(1):1–10

    Article  CAS  PubMed  Google Scholar 

  • Von Rosenstiel P (2007) Brivaracetam (UCB 34714). Neurother 4(1):84–87

    Article  CAS  Google Scholar 

  • Zaccara G, Franciotta D, Perucca P (2007) Idiosyncratic adverse reaction to antiepileptic drugs. Epilepsia 48:1223–1244

    Article  CAS  PubMed  Google Scholar 

  • Zaccara G, Giovannelli F, Cincotta M, Verrotti A, Grillo E (2013) The adverse profile of Perampanel: meta-analysis of randomized controlled trials. Eur J Neurol 20:1204–1211

    Article  CAS  PubMed  Google Scholar 

  • Zona C, Niespodziany I, Pieri M, Klitgaard H, Margineanu DG (2005) Seletracetam (ucb 44212), a new pyrrolidone derivative, lacks effect on Na + currents in rat brain neurons in vitro. Epilepsia 46(Suppl 8):116

    Google Scholar 

  • Zona C, Pieri M, Carunchio I, Curcio L, Klitgaard H, Margineanu DG (2010) Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Epilepsy Res 88(1):46–54

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Unit, S. Anna Hospital, Como, Italy

    Vincenzo Belcastro

  2. Department of Paediatric, University of Perugia, Perugia, Italy

    Alberto Verrotti

Authors
  1. Vincenzo Belcastro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Verrotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Belcastro .

Editor information

Editors and Affiliations

  1. DINOGMI, University of Genoa, Genova, Genova, Italy

    Pasquale Striano

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Belcastro, V., Verrotti, A. (2015). Novel Molecular Targets for Drug-Treatment of Epilepsy. In: Striano, P. (eds) Epilepsy Towards the Next Decade. Contemporary Clinical Neuroscience. Springer, Cham. https://doi.org/10.1007/978-3-319-12283-0_10

Download citation

Publish with us

Policies and ethics

Search

Navigation